아웃룩 테라퓨틱스(OTLK)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $0.76 (-14.90%), 시가총액 $0.03B, 52주 범위 $0.20 ~ $2.97.
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin,
아웃룩 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
아웃룩 테라퓨틱스의 현재 주가는 $0.76 (-14.90%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
아웃룩 테라퓨틱스의 시가총액은 약 $0.03B입니다.
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candida